Altre lingue Inspira Technologies Oxy B.H.N. Ltd.

Azioni

IINN

IL0011715781

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 30/04/2024			Variaz. 5gg	Var. 1 gen.
1,88 ^USD	+0,53%		+1,08%	+77,36%

17/04	Inspira Technologies OXY B.H.N. Ltd firma un contratto di collaborazione con l'Ospedale Beilinson in Israele per la valutazione del suo dispositivo proprietario INSPIRA ART100 nelle procedure di trapianto di organi.	CI
10/04	I risultati dello studio in vitro di Inspira?? e Ennocure mostrano una prevenzione del 100% della crescita batterica che causa infezioni del flusso sanguigno.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Inspira Technologies OXY B.H.N. Ltd Signs Collaboration Term Sheet with the Beilinson Hospital in Israel for the Evaluation of Its Proprietary INSPIRA ART100 device in Organ Transplant Procedures	17/04
Inspira, Beilinson Hospital Collaborate on Organ Transplant Device Evaluation	16/04
Inspira?? and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth Causes Bloodstream Infections	10/04
Inspira? Technologies Oxy B.H.N. Ltd. Announces Program to Pioneer the Applicable Use of the INSPIRA? ART100 Device for an Artificial Womb	03/04
Inspira Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager	02/04
Inspira Technologies Reports Full Year 2023 Financial Results	26/03
Inspira Technologies Oxy B.H.N. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Inspira Technologies OXY B.H.N. Ltd. Announces AMAR Regulatory Submission of the INSPIRA? ART100, to Enter the Southeast Asia and South American Markets	18/03
Inspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator	12/03
INSPIRA TECHNOLOGIES OXY B H N : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS - Form 6-K	08/03
INSPIRA TECHNOLOGIES OXY B H N : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS - Form 6-K	04/03
Inspira Technologies Oxy B.H.N. Ltd. Plans to Report the Primary Results for A Core Blood Oxygenation Technology Within Days	04/03
Inspira Announces Breakthrough Update, Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements	28/02
Inspira to Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone	28/02
Inspira Technologies Oxy B.H.N. Ltd. Announces Approval from the U.S. Food & Drug Administration for its INSPIRA ART100 in the First Half of 2024	27/02
Inspira Technologies OXY B.H.N. Ltd. Introduces High-End Platform for Bio-Mimicking Blood parameters for Development and Testing of Core Technologies	22/02
Inspira Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System	15/02
Sector Update: Health Care Stocks Gain Late Afternoon	14/02
Sector Update: Health Care Stocks Rise in Afternoon Trading	14/02
Sector Update: Health Care	14/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Inspira Technologies Oxy B.H.N. Ltd.

Azioni

IINN

IL0011715781

Altre lingue

Filtri